Macquarie Group Ltd. grew its holdings in shares of Juno Therapeutics, Inc. (NASDAQ:JUNO) by 17.5% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 9,750 shares of the biopharmaceutical company’s stock after acquiring an additional 1,450 shares during the quarter. Macquarie Group Ltd.’s holdings in Juno Therapeutics were worth $437,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Teachers Advisors LLC raised its stake in Juno Therapeutics by 15.4% during the second quarter. Teachers Advisors LLC now owns 74,255 shares of the biopharmaceutical company’s stock worth $2,219,000 after acquiring an additional 9,890 shares in the last quarter. DekaBank Deutsche Girozentrale raised its stake in Juno Therapeutics by 27.9% during the third quarter. DekaBank Deutsche Girozentrale now owns 61,900 shares of the biopharmaceutical company’s stock worth $1,712,000 after acquiring an additional 13,500 shares in the last quarter. Northern Trust Corp increased its stake in shares of Juno Therapeutics by 11.8% in the second quarter. Northern Trust Corp now owns 382,631 shares of the biopharmaceutical company’s stock valued at $11,438,000 after buying an additional 40,468 shares during the period. Candriam Luxembourg S.C.A. acquired a new position in shares of Juno Therapeutics in the third quarter valued at approximately $5,428,000. Finally, State Street Corp increased its stake in shares of Juno Therapeutics by 7.4% in the second quarter. State Street Corp now owns 3,236,384 shares of the biopharmaceutical company’s stock valued at $96,742,000 after buying an additional 222,754 shares during the period. 70.37% of the stock is owned by hedge funds and other institutional investors.

Several research analysts have recently issued reports on JUNO shares. Citigroup reaffirmed a “buy” rating and issued a $59.00 price objective on shares of Juno Therapeutics in a research note on Tuesday, October 31st. Cowen reaffirmed a “buy” rating and issued a $49.00 price objective on shares of Juno Therapeutics in a research note on Friday, October 27th. Maxim Group reaffirmed a “buy” rating and issued a $56.00 price objective (up previously from $34.00) on shares of Juno Therapeutics in a research note on Monday, October 9th. SunTrust Banks raised Juno Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, November 2nd. Finally, Raymond James Financial reaffirmed a “buy” rating on shares of Juno Therapeutics in a research note on Monday, December 11th. Three research analysts have rated the stock with a sell rating, eight have given a hold rating and eight have given a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $45.48.

In other Juno Therapeutics news, insider Sunil Agarwal sold 7,285 shares of the stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $44.76, for a total transaction of $326,076.60. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Robert Azelby sold 6,666 shares of the stock in a transaction that occurred on Thursday, November 2nd. The stock was sold at an average price of $54.95, for a total value of $366,296.70. Following the transaction, the executive vice president now owns 79,998 shares in the company, valued at $4,395,890.10. The disclosure for this sale can be found here. Corporate insiders own 15.08% of the company’s stock.

Shares of Juno Therapeutics, Inc. (NASDAQ JUNO) opened at $44.68 on Friday. Juno Therapeutics, Inc. has a twelve month low of $17.52 and a twelve month high of $63.45. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.77 and a quick ratio of 4.77.

Juno Therapeutics (NASDAQ:JUNO) last announced its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.73) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.80) by $0.07. Juno Therapeutics had a negative return on equity of 32.54% and a negative net margin of 332.05%. The business had revenue of $44.80 million for the quarter, compared to analysts’ expectations of $18.12 million. During the same period in the prior year, the business posted ($0.57) earnings per share. The firm’s revenue was up 115.4% on a year-over-year basis. equities analysts anticipate that Juno Therapeutics, Inc. will post -4.02 EPS for the current year.

WARNING: This piece of content was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another domain, it was copied illegally and republished in violation of international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/12/16/juno-therapeutics-inc-juno-shares-bought-by-macquarie-group-ltd.html.

Juno Therapeutics Company Profile

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

Institutional Ownership by Quarter for Juno Therapeutics (NASDAQ:JUNO)

Receive News & Stock Ratings for Juno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics and related stocks with our FREE daily email newsletter.